Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Spyre Therapeutics Inc. (SYRE)

NASDAQ: SYRE · Pharmaceutical Preparations · Waltham, MA

Our rating: Neutral

Call changed from Cautious to Neutral at $99.04, moderate conviction, November 4, 2026.

Breaks if: The Neutral call turns Cautious if two consecutive quarterly filings show free cash flow burn exceeding $55 million per quarter without an accompanying financing that extends the implied runway beyond eight quarters — that combination would signal accelerating consumption on a timetable the current capitalization cannot comfortably support. It turns Positive if a pivotal trial for the lead program reports a statistically significant primary endpoint at the pre-specified alpha within the next twelve months and management provides initial commercial guidance, as that would convert pipeline optionality into a credible near-term revenue forecast.

Key figures

Market value$8.9B
Revenue, last 12 monthsn/a
Net income, last 12 months−$264M
Free cash flow, last 12 monthsn/a
Price to earningsn/a
Free cash flow yieldn/a
Dividend yield0.0%
Operating marginn/a
Return on equity−35.0%
Beta to the S&P 5001.67
Volatility, annualized68.6%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026n/an/a$-0.95n/a
June 30, 2026n/an/a$-0.35n/a
March 31, 2026n/an/a$-0.74n/a
December 31, 2025n/an/an/an/a
September 30, 2025n/an/a$-0.15n/a
June 30, 2025n/an/an/an/a
March 31, 2025n/an/an/an/a
December 31, 2024$0.00n/an/an/a

29 ledger entries and 68 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.